TRASYLOL

This brand name is authorized in Austria, Finland, France, Ireland, Malta, New Zealand, Poland, Romania, Singapore, Turkey, South Africa

Active ingredients

The drug TRASYLOL contains one active pharmaceutical ingredient (API):

1 Aprotinin UNII 04XPW8C0FL - APROTININ

Aprotinin is a broad spectrum protease inhibitor which has antifibrinolytic properties. By forming reversible stoichiometric enzyme-inhibitor complexes, aprotinin acts as an inhibitor of human trypsin, plasmin, plasma kallikrein and tissue kallikrein, thus inhibiting fibrinolysis. Read about Aprotinin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B02AB01	Aprotinin	B Blood and blood forming organs → B02 Antihemorrhagics → B02A Antifibrinolytics → B02AB Proteinase inhibitors
Discover more medicines within B02AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 447982
Country: FR	Base de données publique des médicaments	Identifier(s): 65436166
Country: MT	Medicines Authority	Identifier(s): AA1411/00401
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 1222
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100129127
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68337001
Country: SG	Health Sciences Authority	Identifier(s): 07805P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699546691289
Country: ZA	Health Products Regulatory Authority	Identifier(s): H/32/2912